InvestSMART
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Managed Funds
  5. Blue Sky Venture Capital Serene Fund - Managed fund profile

Blue Sky Venture Capital Serene Fund - Managed Fund

Fund Objective
The Blue Sky Venture Capital Serene Fund ('Fund') offers investors who have invested in the VC2012 Fund and the VC2014 Fund the opportunity to make further investment in Serene Medical Pty Ltd ('Serene' or the 'Company').
Fund Strategy
Serene has developed NeuBelleTM, a medical device that is the first neurotoxin-free, long lasting procedure to relax dynamic lines caused by facial muscles. It has been likened to a safer, longer lasting alternative to Botox. The device has been FDA-cleared for precisely locating a motor nerve (by stimulating a reflex) and simultaneously using radio frequency to interrupt the signal pathway of the nerve to the muscles that are controlled by the nerve via a thermal lesion.

Fund Performance Comparison

Relative Fund Performance vs {{ fund.benchmark.peers.peerCount }} peers using {{ fund.benchmark.name }} as their benchmark.

{{ fund.name }}
Peers
Benchmark ({{ fund.benchmark.name }})
{{ fund.model.name }}
The performance of the peers is calculated as the total of the performance for each time period for all the funds in the peer group, divided by the number of funds in the peer group.
grow your money
Grow your money, not your fees
It's fees rather than returns that make the biggest difference to your investment's compounding returns.
Free Fees Report
investing
Investing made simple
Our professionally-tailored investment portfolios consistently beat most of our peers.
Free investor guide
Grow your money, not your fees
It's fees rather than returns that make the biggest difference to your investment's compounding returns. Free Fees Report
Investing made simple
Our professionally-tailored investment portfolios consistently beat most of our peers. Free investor guide

Fees Comparison

{{ fund.mer | number:2 }}
% p.a.
{{ fund.name }}
{{ modelPortfolio.mer * 100 | number:2 }}
% p.a.
{{ modelPortfolio.name }}
{{ fund.benchmark.peers.mer * 100 | number:2 }}
% p.a.
Average of peers ({{ fund.benchmark.peers.peerCount }})
NOTE: Fee data has been provided by Morningstar, it may not include all costs being charged on your investment such as platform and adviser fees. You should check your fund manager or adviser statements to find out the exact fees you are being charged. Peers are funds that use the same benchmark in the Morningstar database.
Upsell Banner

Fund performance

  1M 3M 6M 1Y p.a. 2Y p.a. 3Y p.a. 5Y p.a. 10Y p.a.
Total return -% -% -% -0.38% -5.77% -21.37% -% -%
Growth return -0.38% -0.38% -0.38% -0.38% -5.77% -21.37% -% -%
Income return -% -% -% 0% 0% 0% -% -%
Market index (RBA Bank accepted Bills 90 Days)
Total return 0.3% 0.91% 1.91% 4.09% 4.22% 4% 2.52% 2.06%
As at 30 Jun 2022. Returns for periods greater than 1 year are annualised. All figures are percentages.

Asset Allocation

No asset allocation data available.
Average Allocation of Peers
Alternatives
22.40%
Australian Equities
3.94%
International Equities
6.69%
Cash
44.85%
Property & Infrastructure
1.44%
Fixed Interest
20.69%

General Information

Fund Details
Type Description
Blue Sky Venture Capital Serene Fund
Blue Sky Private Equity Limited
Miscellaneous
Not Rated
Investment Fund
4 Jul 2017
n/a
$0.0526 (as at 30 Jun 2022)
$0.0526 (as at 30 Jun 2022)
Finalised
Offer information
Type Description
Minimum initial investment $25,000

FAQs about the Blue Sky Venture Capital Serene Fund

The objective of the Blue Sky Venture Capital Serene Fund managed fund is The Blue Sky Venture Capital Serene Fund ('Fund') offers investors who have invested in the VC2012 Fund and the VC2014 Fund the opportunity to make further investment in Serene Medical Pty Ltd ('Serene' or the 'Company').

The strategy of the Blue Sky Venture Capital Serene Fund managed fund is Serene has developed NeuBelleTM, a medical device that is the first neurotoxin-free, long lasting procedure to relax dynamic lines caused by facial muscles. It has been likened to a safer, longer lasting alternative to Botox. The device has been FDA-cleared for precisely locating a motor nerve (by stimulating a reflex) and simultaneously using radio frequency to interrupt the signal pathway of the nerve to the muscles that are controlled by the nerve via a thermal lesion.

The APIR code of the Blue Sky Venture Capital Serene Fund managed fund is .

Blue Sky Venture Capital Serene Fund’s total return last month was -%. This was made up of a growth return of -0.38% and an income return of -%. These returns were calculated as at 30 Jun 2022.

Blue Sky Venture Capital Serene Fund’s total return for the last three months was -%. This was made up of a growth return of -0.38% and an income return of -%%. These returns were calculated as at 30 Jun 2022.

Blue Sky Venture Capital Serene Fund’s one-year total return is -0.38%. This was made up of a growth return of -0.38% and an income return of 0%. These returns were calculated as at 30 Jun 2022.

Blue Sky Venture Capital Serene Fund’s one-year total return is -21.37%. This was made up of a growth return of -21.37% and an income return of 0%. These returns were calculated as at 30 Jun 2022.

The asset allocation of the Blue Sky Venture Capital Serene Fund managed fund is :

Alternatives
100%
Australian Equities
0%
International Equities
0%
Cash
0%
Property & Infrastructure
0%
Fixed Interest
0%

The Responsible Entity for the Blue Sky Venture Capital Serene Fund managed fund is Blue Sky Private Equity Limited.

The Blue Sky Venture Capital Serene Fund managed fund belongs to the Miscellaneous sector/asset class.

As at , the size of the Blue Sky Venture Capital Serene Fund managed fund was $ million.

The Blue Sky Venture Capital Serene Fund managed fund has an inception date of 4 Jul 2017.

The current entry price of the Blue Sky Venture Capital Serene Fund managed fund is $0.0526 per unit and the current exit price is $0.0526 per unit (as at 30 Jun 2022).

The current exit price of the Blue Sky Venture Capital Serene Fund managed fund is $0.0526 per unit and the current entry price is $0.0526 per unit (as at 30 Jun 2022).

The minimum initial investment amount for the Blue Sky Venture Capital Serene Fund managed fund is $25,000.

Fund data sourced from Morningstar. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only. Whilst every care has been taken in producing these numbers, neither Morningstar nor InvestSMART can make any guarantees around the complete accuracy of these figures. Should you decide to change investments, please read all relevant disclosure documents including the Product Disclosure Statements and if required, you may consider speaking to a financial professional for further guidance. A tax event may be realised as a result of switching investments. Past performance is not a reliable indicator of future performance.